HURA
What one share of TuHURA BIOSCIENCES, INC./NV holds
Pharmaceutical Preparations
We are a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies.
TuHURA BIOSCIENCES, INC./NV’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.54 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.53 |
| Cash and investments | $0.02 |
| Debt | $0.06 |
| Book value | $0.29 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2021 | — | −$80.17 | — | −$36.43 | — | $12.25 |
| 2022 | — | −$25.80 | $0.18 | −$21.12 | — | $7.30 |
| 2023 | — | −$9.27 | — | −$7.32 | — | $0.42 |
| 2023 | $0.00 | −$2.47 | $0.01 | −$1.01 | — | −$0.13 |
| 2024 | $0.00 | −$1.21 | $0.00 | −$0.79 | — | $1.20 |
| 2025 | $0.00 | −$0.63 | $0.00 | −$0.58 | — | $0.35 |